{"id":"tp-45038","type":"article-newspaper","title":"BioMarin Sees $1.50 Q3 EPS Hit From Alesta Costs Ahead of Results","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/45038","datePublished":"2026-10-30T19:01:51.000Z","dateModified":"2026-10-30T19:01:51.000Z","language":"en","abstract":"The preliminary estimate includes $283 million in pretax acquired research and development expense. BioMarin plans to update its 2026 outlook when it discusses results Monday, Nov. 2.","section":"Business","references":[]}